IBRX holder plans sale of 50,000 shares

A holder of ImmunityBio (symbol IBRX) has filed a Rule 144 notice to sell 50,000 shares of common stock.

Rhea-AI Filing Summary

A holder of ImmunityBio (symbol IBRX) has filed a Rule 144 notice to sell 50,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $197,500 based on the figures in the notice. The filing lists 984,965,179 shares outstanding as a baseline figure for the issuer’s common stock.

The securities to be sold were acquired on 01/16/2026 by an exercise of stock options from the issuer, paid in cash, with the same date shown for payment. By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, consistent with the representations referenced in Rule 144 and any Rule 10b5-1 trading plan disclosures.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the IBRX Form 144 filing disclose?

The Form 144 filing for IBRX discloses a planned sale of 50,000 shares of common stock by a holder relying on Rule 144.

How many IBRX shares are planned to be sold under this Form 144?

The notice covers a proposed sale of 50,000 shares of IBRX common stock.

What is the aggregate market value of the IBRX shares in this Form 144?

The filing lists an aggregate market value of $197,500 for the 50,000 common shares to be sold.

How and when were the IBRX shares in this Form 144 acquired?

The 50,000 IBRX common shares were acquired on 01/16/2026 through an exercise of stock options from the issuer, with payment in cash on the same date.

Which broker and exchange are involved in this IBRX Form 144 sale?

The planned sale will be executed through Morgan Stanley Smith Barney LLC on the NASDAQ exchange.

How many IBRX shares are shown as outstanding in the Form 144?

The Form 144 notes that there are 984,965,179 shares of IBRX common stock outstanding as a baseline figure.

What representation does the seller make in the IBRX Form 144?

By signing, the seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/16/2026 - 04:22 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001849739
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IMMUNITYBIO INC
SEC File Number	001-37507
Address of Issuer	3530 John Hopkins Court San Diego CALIFORNIA 92121
Phone	8446965235
Name of Person for Whose Account the Securities are To Be Sold	CHRISTOBEL SELECKY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	50000	197500.00	984965179	01/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/16/2026	Exercise of Stock Options	Issuer			50000	01/16/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	01/16/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Christobel Selecky
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)